{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:56:09Z","timestamp":1787043369879,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.xjidi.2023.100217","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T11:38:48Z","timestamp":1688816328000},"page":"100217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Mendelian Randomization Analysis reveals Inverse Genetic Risks between Skin Cancers and Vitiligo"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4001-2335","authenticated-orcid":false,"given":"Sarem","family":"Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3566-0160","authenticated-orcid":false,"given":"Ivan","family":"Molotkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-3029","authenticated-orcid":false,"given":"Nikolai","family":"Klebanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1261-235X","authenticated-orcid":false,"given":"Michael","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0949-8752","authenticated-orcid":false,"given":"Mark J.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-8764","authenticated-orcid":false,"given":"Mykyta","family":"Artomov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2204-2071","authenticated-orcid":false,"given":"Hensin","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2023.100217_bib1","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.jaad.2013.01.012","article-title":"Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma","volume":"69","author":"Alonso-Castro","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/1097-0142(19940315)73:6<1621::AID-CNCR2820730613>3.0.CO;2-E","article-title":"Antiphospholipid syndrome associated with immunotherapy for patients with melanoma","volume":"73","author":"Becker","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.xjidi.2023.100217_bib3","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/ng.411","article-title":"Genome-wide association study identifies three loci associated with melanoma risk","volume":"41","author":"Bishop","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.xjidi.2023.100217_bib4","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","article-title":"Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma","volume":"126","author":"Boasberg","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/pcmr.12948","article-title":"Genetics of DNA Methylation Consortium, Elliott HR. Investigating DNA methylation as a potential mediator between pigmentation genes, pigmentary traits and skin cancer","volume":"34","author":"Bonilla","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.xjidi.2023.100217_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41467-019-14156-4","article-title":"A\u00a0robust and efficient method for Mendelian randomization with hundreds of genetic variants","volume":"11","author":"Burgess","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.xjidi.2023.100217_bib7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/archderm.1987.01660320095019","article-title":"Prognostic significance of hypopigmentation in malignant melanoma","volume":"123","author":"Bystryn","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.634553","article-title":"Integrative analysis of omics data reveals regulatory network of CDK10 in vitiligo risk","volume":"12","author":"Cai","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.xjidi.2023.100217_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.xjidi.2023.100217_bib10","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1056\/NEJMc1508163","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"373","author":"Chan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2023.100217_bib11","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xjidi.2023.100217_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2023.100217_bib13","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/ng.161","article-title":"ASIP and TYR pigmentation variants associate with\u00a0cutaneous melanoma and basal cell carcinoma [published correction\u00a0appears in Nat Genet 2008;40:1029]","volume":"40","author":"Gudbjartsson","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.xjidi.2023.100217_bib14","doi-asserted-by":"crossref","first-page":"djv221","DOI":"10.1093\/jnci\/djv221","article-title":"Gender disparity and mutation burden in metastatic melanoma","volume":"107","author":"Gupta","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.xjidi.2023.100217_bib15","article-title":"Orienting the causal relationship between imprecisely measured traits using GWAS summary data","volume":"13","author":"Hemani","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1016\/j.xjidi.2023.100217_bib16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"ELife"},{"key":"10.1016\/j.xjidi.2023.100217_bib17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jaad.2008.09.033","article-title":"Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo","volume":"60","author":"Hexsel","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib19","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/ng.3680","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Jin","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.xjidi.2023.100217_bib20","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo","volume":"362","author":"Jin","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2023.100217_bib21","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/jid.2012.37","article-title":"Next-generation DNA re-sequencing identifies common variants of TYR and HLA-A that modulate the risk of generalized vitiligo via antigen presentation","volume":"132","author":"Jin","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib22","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/s41598-019-41015-5","article-title":"Burden of unique and low prevalence somatic mutations correlates with cancer survival","volume":"9","author":"Klebanov","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2023.100217_bib23","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A\u00a0review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kr\u00fcger","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41588-020-0611-8","article-title":"Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility","volume":"52","author":"Landi","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.xjidi.2023.100217_bib25","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1093\/hmg\/ddz121","article-title":"Combined analysis of keratinocyte cancers identifies novel genome-wide loci","volume":"28","author":"Liyanage","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.xjidi.2023.100217_bib26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.xjidi.2023.100217_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamadermatol.2017.1679","article-title":"Nivolumab therapy for treatment-related vitiligo in a patient with relapsed metastatic melanoma","volume":"153","author":"Nakamura","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2340\/00015555-3199","article-title":"Vitiligo repigmentation with melanoma progression during pembrolizumab treatment","volume":"99","author":"Nardin","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xjidi.2023.100217_bib30","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/pcmr.12161","article-title":"Melanoma-associated leukoderma\u2014immunology in black and white?","volume":"26","author":"Naveh","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.xjidi.2023.100217_bib32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0190-9622(83)70182-9","article-title":"Vitiligo in patients with metastatic melanoma: A good prognostic sign","volume":"9","author":"Nordlund","year":"1983","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib33","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo","volume":"71","author":"Paradisi","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdp325","article-title":"Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study","volume":"21","author":"Quaglino","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.xjidi.2023.100217_bib35","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaophthalmol.2013.4254","article-title":"Cutaneous vitiligo following management of uveal melanoma in 6 patients","volume":"131","author":"Rishi","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xjidi.2023.100217_bib36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(93)90572-8","article-title":"Pigmentation phenotypes of variant extension locus alleles result from\u00a0point mutations that alter MSH receptor function","volume":"72","author":"Robbins","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.xjidi.2023.100217_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.det.2016.11.003","article-title":"Skin cancer risk (nonmelanoma skin cancers\/melanoma) in vitiligo patients","volume":"35","author":"Rodrigues","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.xjidi.2023.100217_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000057881","article-title":"Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed Caucasian patients with vitiligo","volume":"204","author":"Schallreuter","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.xjidi.2023.100217_bib39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/pcmr.12942","article-title":"The structure and function of the mouse tyrosinase locus","volume":"34","author":"Seruggia","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.xjidi.2023.100217_bib40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/exd.13069","article-title":"Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo","volume":"26","author":"Speeckaert","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.xjidi.2023.100217_bib42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjd.12111","article-title":"Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners","volume":"168","author":"Teulings","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fgene.2016.00095","article-title":"Melanocortin 1 receptor: structure, function, and regulation","volume":"7","author":"Wolf Horrell","year":"2016","journal-title":"Front Genet"},{"key":"10.1016\/j.xjidi.2023.100217_bib44","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.jid.2018.03.1511","article-title":"Inverse relationship between vitiligo-related genes and skin cancer risk","volume":"138","author":"Wu","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2023.100217_bib45","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1038\/s41598-022-11681-z","article-title":"Functional divergence of the pigmentation gene melanocortin-1 receptor (MC1R) in six endemic Macaca species on Sulawesi Island","volume":"12","author":"Yan","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2023.100217_bib46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: A pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm Venereol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026723000425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026723000425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:04:57Z","timestamp":1763021097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026723000425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2667026723000425"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2023.100217","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mendelian Randomization Analysis reveals Inverse Genetic Risks between Skin Cancers and Vitiligo","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2023.100217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100217"}}